Introduction
Vascular endothelial growth factor (VEGF) is not only an important regulator of physiological angiogenesis but also involved in pathological neovascularization. 1 Formation of new blood vessels caused by the overproduction of growth factors such as VEGF is a key component of diseases such as wet age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR) and tumor growth. [2] [3] [4] Blocking of VEGF with antibodies, soluble VEGF receptors (sVEGFR) or inhibition of VEGF receptor (VEGFR) tyrosine kinase activity are useful strategies that have shown promising preclinical and clinical results. [4] [5] [6] Ranibizumab, an anti-VEGF drug given intravitreally to wet-AMD patients results in substantially improved visual acuity. 7 Intraocular gene delivery of VEGF antagonists could have theoretical advantages over the current treatment, which requires monthly intravitreal injections (for years) by a retinal specialist.
The angiogenic effect of VEGF is mediated predominantly by its binding to VEGFR KDR. 8 Another high-affinity VEGFR, Flt-1, binds VEGF about 10 times stronger than KDR, however Flt-1 activation does not significantly stimulate angiogenesis. 9, 10 Both receptors, Flt-1 and KDR, have similar structure with extracellular regions consisting of seven domains, 1-7. 10, 11 There exists another naturally occurring soluble form of Flt-1 (sFlt-1) that contains only the extracellular domains and has the same VEGF-binding affinity as full-length Flt-1. 11, 12 The VEGF-binding function of Flt-1 has been mapped to the second domain. [13] [14] [15] [16] There have been previous studies with two truncated soluble receptor hybrids, Flt(1-3)-IgG and Flt(1-7)-IgG, consisting of either the first three domains or all seven domains fused to human IgG1-Fc region. 13 The molecule Flt(1-3)-IgG was reported to have the same VEGF-binding affinity as Flt(1-7)-IgG, however Flt(2)-IgG that contains only second domain was not capable of inhibiting VEGF. 13, 17 Another molecule called VEGF-Trap, generated by the second domain of Flt-1 fused to the third domain of KDR and human IgG1-Fc region, has been shown to be a very potent VEGF binder. 18 Adeno-associated virus (AAV) vectors offer an attractive tool for intraocular gene delivery because of their nonpathogenic nature, low toxicity, minimal immunogenicity and long-term persistence. [19] [20] [21] [22] Intravitreal administration of AAV serotype 2 (AAV2) vector in mice results mostly in transduction of ganglion cells and few cells in the inner nuclear layer. 21 Subretinal delivery of AAV2 vector encoding full-length sFlt-1 (transduction of photoreceptors and retinal pigmented epithelium) prevented development of laser-induced choroidal neovascularization in all treated monkeys. 22 In this study we have designed and constructed small novel soluble hybrid molecules that have strong anti-VEGF activity in vitro, incorporated these molecules into AAV2 vectors and then tested in vivo persistence of expression and efficacy and safety following intravitreal delivery of these AAV2-based vectors in the oxygeninduced retinopathy of prematurity (OIR) mouse model.
Results

sFLT01 molecule inhibits VEGF-mediated cell proliferation
We first constructed molecules D1-3, sFLT01 and D2-Fc (Figure 1a) . The molecule D1-3 has served a positive control for VEGF binding and contains first three Flt-1 domains. The second molecule, sFLT01, contains only one Flt-1 domain 2 linked by 9Gly to the human IgG1 heavy-chain Fc region that resulted in the generation of a forced homodimer. The formation of sFLT01 dimers was confirmed by western blot analysis (Figure 2b) . The third molecule, D2-Fc, is identical to sFLT01, except it does not contain 9Gly linker. Plasmids encoding these molecules under control of a cytomegalovirus (CMV) promoter were used for transfection of 293 cells and the conditioned media (CM) were evaluated for their ability to block VEGF-stimulated human umbilical vein endothelial cells (HUVECs) proliferation (Figure 1b) . The molecule D2-Fc was not able to neutralize VEGF and inhibit HUVECs proliferation whereas sFLT01 demonstrated an efficient inhibition of VEGF-dependent HUVECs proliferation (Figure 1b ).
IgG1 CH3 domain and peptide linker are important in VEGF binding
Using the sFLT01 as a parental molecule, we generated several mutant derivatives with various deletions along the IgG1-Fc region. When comparing several constructs with various deletions either in CH2 or in CH3 domains of IgG1, we have observed that the CH3 domain is involved in preserving the VEGF-binding function (data not shown). The molecule sFLT02, where the second domain of Flt-1 was linked to the IgG1 CH3 domain through 9Gly (Figures 2a and b) , retained the VEGFbinding function (Figure 2c ). This set of proliferation assays was performed using a different lot of HUVECs (not the same lot as used in Figure 1b) and it demonstrates that sFLT01 has comparable VEGF block- Data are expressed as mean±s.d. where 'n' represents the number of independent proliferation experiments (for sFLT01 and D2-Fc, n ¼ 3; for D1-3, n ¼ 2). Student's non-paired t-test; **Po0.005 for difference between '+VEGF control' and 'VEGF binder'; D1-3 (n ¼ 2) was not included in statistics. ). Hence we conclude that the presence of both the CH3 domain and the peptide linker facilitates VEGF binding. Western blot analyses of sFLT02 and D2-CH3 (Figure 2b ) show a prevalence of the dimeric forms for both proteins under nonreducing conditions ruling out the possibility that the lack of efficacy of D2-CH3 is due to its inability to dimerize.
For the next construct we used another type of linker, the 15-mer (Gly 4 Ser) 3 .
23 D2-(Gly 4 Ser) 3 -Fc protein was generated and it contained Flt-1 domain 2, (Gly 4 Ser) 3 linker and the IgG1 Fc. The molecule D2-(Gly 4 Ser) 3 -Fc was further characterized in HUVECs proliferation assay. Biological activity of D2-(Gly 4 Ser) 3 -Fc as measured by inhibition of HUVEC proliferation was similar to that of sFLT01 (data not shown).
sFLT01 binds VEGF better than the other novel constructs
The relative binding affinity between VEGF and our novel molecules was determined using a cell-free assay system. CM containing known concentrations of sVEGFR (ranging from 0.29 to 150 pM) were serially diluted and mixed with VEGF (10 pM final concentration). The amount of unbound VEGF was then measured by a human VEGF-specific ELISA. sFLT01 binds VEGF with higher affinity than D1-3, sFLT02 and D2-CH3, where the latter showed a minimal VEGF-binding affinity (Figure 3 ). These data are in agreement with our HUVECs proliferation assays shown in Figures 1 and 2. AAV2.sFLT01 transgene and mRNA localization AAV2-based vectors were constructed encoding sFLT01 and adult C57BL/6 mice were intravitreally injected with 2.2 Â 10 9 drps (DNase resistant particles) of AAV2.sFLT01. The animals were killed 28 days following injection and the eyes were processed for histological sectioning. The presence of sFLT01 protein and mRNA was confirmed by immunofluorescence and by in situ hybridization. sFLT01 protein was predominantly observed in the retinal ganglion cells of mouse retinas (Figure 4a) . Infrequently, cells deeper in the retina (presumably Mü ller cells) were also shown to contain the sFLT01 protein. Another set of retinas was examined using in situ hybridization to detect the mRNA of the sFLT01 transgene. The retinal ganglion cells were the predominant cell type transduced in the mouse retina (Figure 4c ). No sFLT01 protein was detected in the uninjected control eyes. No sFLT01 mRNA message was detected in the AAV2.sFLT01 injected eyes when sense probe was used.
Longevity of transgene expression
Adult C57BL/6 mice were intravitreally injected with 1 Â 10 9 drps of AAV2.sFLT01. Animals were killed at predetermined time points and the level of sFLT01 was measured in individual eyes (homogenates of retina and vitreous humor) by ELISA against human Flt-1. The samples from each time point were assayed separately for animals treated with AAV2.sFLT01 ( Figure 5 ). The data suggest that AAV2-mediated delivery of sFLT01 results in long-term stable protein expression in the murine eye with no transgene-related toxicities observed. The apparent rise in sFLT01 in the 12-month AAV2.sFLT01 cohort was due to a change in the tissue homogenization protocol.
AAV2.sFLT01 intravitreal delivery inhibits angiogenesis in OIR model
The efficacy of AAV2.sFLT01 was examined in vivo using OIR mouse model. 24 AAV2.sFLT01 was intravitreally administered into left eyes of neonatal C57BL/6 mice in a dose of 1 Â 10 9 drps per animal. Data shown in Figure 6 were expressed as percentage of neovascularization of untreated eyes in the AAV2.sFLT01 group (n ¼ 43), or between left and right eyes in the control group (n ¼ 26). The occurrence of neovascularization was significantly reduced to 54 ± 47% in AAV2.sFLT01-treated eyes (AAV1.sFLT01 group) as compared to 102±66% between left and right eyes in the control group (mean±s.d.). Treatment with AAV2.sFLT01 significantly reduced ocular neovascularization (Student's t-test; Po0.0009) compared to the untreated contralateral eyes.
Discussion
Many reports from preclinical and clinical studies demonstrate that antagonizing VEGF is a potentially useful strategy for treatment of pathological neovascularization which is a key component of ocular diseases like wet-AMD or PDR. In this study, we have developed several novel hybrid molecules that inhibit VEGF in vitro and are capable of inhibiting ocular neovascularization in vivo. It has been reported that domain 2 of VEGFR Flt-1 requires the presence of flanking sequences from The amount of unbound VEGF (y axis) was measured by a human VEGF-specific enzyme-linked immunosorbent assay (ELISA) in triplicate. The number of independent transfections (n) for each molecule are: sFLT01 (n ¼ 5), D1-3 (n ¼ 3), sFLT02 (n ¼ 2) and D2-CH3 (n ¼ 1). Data are expressed as mean±s.d.; Student's non-paired t-test; ***Po0.0001, **Po0.001 for differences between sFLT01 and D1-3. LOQ, limit of quantitation ¼ 0.371 pM.
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Flt-1 or other VEGFR domains for efficient ligand binding and neutralization. 12, 17 Our results show that domains other than second domain of Flt-1 were not necessary to preserve VEGFR/ligand binding. To obtain Novel anti-VEGF chimeric molecules P Pechan et al dimerization of the soluble receptor, we constructed Flt-1 domain 2 linked directly to IgG1-Fc fragment (molecule D2-Fc), but such a strategy did not enhance its binding to VEGF, in agreement with Davis-Smyth et al. 13 We then have linked the second domain of Flt-1 to Fc through a 9Gly linker, and thus generated a novel molecule, sFLT01, with potent VEGF binding. Our results show, for the first time, that Flt-1 domain 2 does not require presence of other VEGFR domains for high-affinity VEGF binding. Several other constructs where 9Gly was replaced with other short linkers like 15-mer (Gly 4 Ser) 3 , polyglycine pentamer (5Gly) or other random linkers showed VEGF binding comparable to sFLT01.
We also have constructed several other hybrid proteins by deleting selected regions of IgG1 Fc. Although deletion of the entire Fc CH2 domain did not have a significant impact, we find that the CH3 domain is important for VEGF binding of our molecules. The molecule sFLT02, which retains VEGF binding, was generated by the complete deletion of the Fc CH2 domain, such that Flt-1 domain 2 is linked directly to the Fc CH3 domain through the 9Gly linker.
From the variety of gene therapy vectors currently available we first decided to use the AAV vector because of its versatility, safety and long-term in vivo persistence. 25, 26 There are several routes to deliver gene therapy vectors into the eye, however the most common ones are intravitreal and subretinal. 19, 21 We first decided to investigate an intravitreal route of delivery because of its potential ease of use in the retinal clinic. The AAV2.sFLT01 vector predominantly transduced retinal ganglion cells in agreement with previous observation by other investigators. 21 Subretinal delivery of AAV2 encoding full-length sFlt-1 gene has been successfully tested in mouse and in primate models of ocular neovascularization. 22, 27, 28 An adenoviral vector encoding full-length sFlt-1, injected both intravitreously or periocularly suppressed choroidal neovascularization at rupture sites in Bruch's membrane. 29 Our AAV2.sFLT01 vector administered intravitreally to neonatal mice significantly reduced the occurrence of neovascularization in the OIR model. To our knowledge this is the first demonstration of long-term persistent expression of a secreted protein following intravitreal delivery of AAV2 to retinal ganglion cells. There were no gross histological observations of AAV2.sFLT01-related toxicity for the duration of this study (1 year). These results have significant implications for a potential human therapeutic that could be very infrequently administered by a simple intravitreal injection.
Materials and methods
Soluble VEGF receptor hybrids construction
DNAs encoding hybrid sVEGFR molecules were synthesized by DNA 2.0 Inc. (Menlo Park, CA, USA). The construct D1-3 contains the Flt-1 signal peptide sequence and the first three domains of human Flt-1. In all other constructs, the Flt-1 signal peptide sequence was fused directly to Flt-1 domain 2. In molecules D2-Fc, the Flt-1 domain 2 is fused directly to human IgG1-Fc region. The molecule sFLT01 has Flt-1 domain 2 fused to human IgG1-Fc region through the polyglycine 9-mer (9Gly) linker. In molecules sFLT02 and D2-CH3, a shorter fragment of IgG1, domain CH3, was used instead of using the full size of IgG1-Fc region. For initial testing, all hybrid molecules were produced by plasmid transfection of 293 cells followed by harvesting of CM, where the transgenes were under control of the CMV promoter.
HUVEC proliferation assay
Pooled HUVECs were purchased from Cambrex-Lonza (East Rutherford, NJ, USA) and expanded through four passages in EGM-2-MV media (EGM basal media supplemented with bovine brain extract, hEGF, hydrocortisone, gentamicin, amphotericin-B, 5% fetal bovine serum (FBS), VEGF, hFGF-B, R3-IGF-1 and ascorbic acid) according to the manufacturer's instructions. For proliferation assays, HUVECs were seeded at 2 Â 10 3 cells per well in a 96-well culture plate and incubated overnight in M199 starvation media (M199, 5% FBS). The following day, fresh M199 media supplemented with 10 ng ml À1 recombinant human VEGF (R&D Systems, Minneapolis, MN, USA) and CM (5 ml, approximately 1 ng ml À1 of each) from transfected 293 cells containing sVEGFR molecules were added. HUVECs were incubated 3-4 days followed by the addition of the MTS reagent CellTiter 96 AQueous One Solution (Promega, Madison, WI, USA) and incubated for another 2-4 h. Absorbance was measured at OD490 on a VersaMax plate reader using SOFTmax PRO v4.5 (Molecular Devices, Sunnyvale, CA, USA). Data represent the means of independent proliferation experiments (mean ± s.d.) each assayed in triplicate. Each independent proliferation experiment used supernatants from an independent transfection.
Western blot analysis
CM from transfected 293 cells (15 ml), containing proteins of hybrid sVEGFR molecules were analyzed by western blot under nonreduced and reduced conditions. Briefly, samples were separated by SDS-electrophoresis and transferred to polyvinylidene difluoride membrane. Blots were then probed with goat anti-human VEGFR1 horseradish peroxidase antibody conjugate (R&D Systems) followed by detection using ECL Western Blotting Detection Reagent (GE Healthcare Biosciences, Piscataway, NJ, USA).
VEGF-binding assay
Human VEGF (R&D Systems) adjusted to 20 pM in phosphate-buffered saline was mixed with an equal volume of increasing concentrations of sVEGFR molecules (0.001-10 000 pM; final VEGF concentration ¼ 10 pM) overnight at room temperature with gentle shaking. To determine relative binding affinities, samples were assayed for residual unbound VEGF using the Human Quantikine VEGF ELISA kit (R&D Systems), which detects only unbound (noncomplexed) VEGF. VEGF concentration (pM) was plotted as a function of increasing sVEGFR concentration (pM).
AAV vector
Synthetic sFLT01 chimeric transgene was cloned into a plasmid pCBA(2)-int-BGH, obtained from Mark Sands (Washington University Medical School, St Louis, MO, USA), which contains hybrid chicken b-actin (CBA) promoter and bovine growth hormone polyadenylation signal sequence (BGH poly A). 30 The whole sFLT01
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The recombinant vector AAV2.sFLT01 was produced by triple transfection of 293 cells protocol using helper plasmids p5rep-D-CMVcap and pHelper (Stratagene, La Jolla, CA, USA), and purified according to the protocol using an iodixanol step gradient and HiTrap Heparin column (GE Healthcare Life Sciences, Piscataway, NJ, USA) on an Ä KTA FPLC system (GE Healthcare Life Sciences, Piscataway, NJ). 32, 33 The AAV2.sFLT01 viral preparation had a titer of 2.2 Â 10 12 drps (DNase resistant particles) per ml. Viral titers were determined using a real-time TaqMan PCR assay (ABI Prism 7700; Applied Biosystems, Foster City, CA, USA) with primers that were specific for the BGH poly A sequence.
Animals
Adult C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The animals were maintained in Genzyme's AAALAC-accredited vivarium and given free access to food and water throughout the study. All procedures were performed under a protocol approved by the Institutional Animal Care and Use Committee.
Intravitreal injection and OIR model
For the longevity experiment, 9-week-old C57BL/6 mice were intravitreally injected with 1 ml of AAV2.sFLT01 containing 1 Â 10 9 drps of vector and killed 12 months later. For the immunofluorescence and in situ hybridization experiments, adult C57BL/6 mice were intravitreally injected with 1 ml of AAV2.sFLT01 containing 2.2 Â 10 9 drps of AAV2.sFLT01 and killed 28 days later. For the OIR model, neonatal C57BL/6 mouse pups were intravitreally injected on the day of birth (0) with 0.5 ml of AAV2.sFLT01 containing 1.1 Â 10 9 drps of AAV2.sFLT01. The pups and their nursing dam were placed in an isobaric chamber and were exposed to a hyperoxic environment (75% oxygen) from day 7 to 12. 26 The animals from the OIR model were killed on day 17. The eyes of all animals were processed for paraffin embedding and were serially sectioned. A single 5-mm section was taken at each 100-mm level through the entire eye resulting in 10-20 sections to evaluate per eye. The sections were stained with hematoxylin and eosin and the degree of neovascularization was determined by counting the number of endothelial cell nuclei internal to and contiguous with the inner limiting membrane ignoring the region of the regressing hyloid vessels. The number of nuclei in the treated eye was compared to the number of nuclei in the contralateral control eye and the data were expressed as percentage of neovascularization of untreated eyes (mean ± s.d.).
Detection of transgene by immunofluorescence
The sFLT01 transgene was detected in eyes that were fixed in 10% neutral buffered formalin and embedded in paraffin. Tissue sections (5 mm) were prepared and sFLT01 was detected using a goat anti-VEGFR1 primary antibody (R&D Systems) and a fluorescein isothiocyanateconjugated rabbit anti-goat immunoglobulin G (IgG) secondary antibody (Invitrogen Corp., Carlsbad, CA, USA).
Detection of sFLT01 mRNA by in situ hybridization
The sFLT01 mRNA was detected in paraffin-embedded tissue sections by overnight hybridization of a DIGlabeled RNA probe specific for sFLT01. Signal was detected using peroxidase-labeled anti-DIG (Roche Applied Science, Indianapolis, IN, USA) and amplified using both biotinyl tyramide (Dako North America Inc., Carpinteria, CA) and alkaline phosphatase-labeled antibiotin (Alpha Diagnostics International Inc., San Antonio, TX, USA). Fast Red (Dako North America Inc.) was then used to detect the complex, and the sections were counterstained using Mayer's hematoxylin (Dako North America Inc.).
